Breaking News

Vaccinex, Catalent Biologics in ADC Alliance

Will leverage Catalent’s SMARTag and GPEx Technologies, and Vaccinex’s ActivMAb Technology against cancer target

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent Pharma Solutions and Vaccinex, Inc., a clinical-stage biotechnology company, have entered an agreement to develop an antibody-drug conjugate (ADC) using Catalent’s SMARTag conjugation platform and GPEx cell line engineering technologies, and Vaccinex’s ActivMAb technology to develop the ADC against an undisclosed cancer target.   The companies will evaluate the ADC in various preclinical models and move it into cell line and process development, using Catalent’s GPEx technology and de...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters